SlideShare a Scribd company logo
1 of 1
Download to read offline
Interprete el siguiente documento y establezca la importancia de cada una de las
pruebas que allí se anuncian, elabore un ensayo (una hoja) y preparese para foro de
discusión a desarrollar en la clase de correlación clínica se recomienda para ello
llevar información.
The Global Epidemic of Cardiovascular Disease – Diagnostic Standards
and the Role of the Clinical Laboratory in Primary and Secondary Prevention
and Risk Stratification
Professor M. J. McQueen
There is a global epidemic of atherosclerosis and the future disease burden is probably
underestimated because projections do not account for potential increases in risk factors
such as obesity, diabetes, dyslipidemia, hypertension, smoking, and urbanization.
Population based studies now suggest that 80% to 90% of CVD susceptibility can be
explained by a relatively small number of “classical” risk factors. However, myocardial
infarction occurs in up to 50% of people without significant lipid abnormalities and this
has led to the investigation of novel risk factors such as lipoprotein(a), ApoA1, ApoB,
homocysteine, inflammatory markers, infectious markers, and oxidative stress factors.
The clinical laboratory has a significant role in diagnosis, risk stratification, management
and prognosis in acute coronary syndromes, as well as the primary and secondary
prevention of cardiovascular disease.
Myocardial infarction has been re-defined, giving primacy to the rise and fall of
biochemical markers of myocardial necrosis (troponin/CK-MB) accompanied by at least
one of several symptoms and signs. This has created analytical issues for the clinical
laboratory. The biochemical markers may be cardio-specific but there is still not one
which is ischemic heart disease specific, so various markers for myocardial ischemia
have been investigated. Inflammatory markers have been shown to have prognostic
value in identifying those patients with acute coronary syndrome who are at greater risk
of death or myocardial infarction.
For primary and secondary prevention of cardiovascular disease, lipids and lipoproteins,
LP(a), homocysteine, and many inflammatory markers such as oxidized LDL, IL1,
TNF-α, ICAM, VCAM, selectins, IL6, SAA, and CRP have all been investigated. The
evidence for hsCRP as a risk marker for subsequent cardiovascular events is more clearly
demonstrated in primary prevention than secondary prevention cohorts. Data will be
presented from our Heart Outcomes Prevention Evaluation (HOPE) study relating to
inflammatory markers, multiple infection, heat shock proteins and their relative risk for
subsequent cardiovascular events. There is a need for more research to further define the
approach to therapeutic decision making, using markers of inflammation, infection, and
ventricular dysfunction (eg, natriuretic peptides).
File:shd.CV abstract

More Related Content

What's hot

Atherosclerosis and myocardial infarction
Atherosclerosis and myocardial infarctionAtherosclerosis and myocardial infarction
Atherosclerosis and myocardial infarctionautumnpianist
 
Coronary atherosclerosis (6)
Coronary atherosclerosis (6)Coronary atherosclerosis (6)
Coronary atherosclerosis (6)medicinaingles1
 
Leukemia --acute myeloid leukemia --- magdi sasi
Leukemia  --acute myeloid leukemia --- magdi sasiLeukemia  --acute myeloid leukemia --- magdi sasi
Leukemia --acute myeloid leukemia --- magdi sasicardilogy
 
Homocysteine and Atherosclerosis
Homocysteine and AtherosclerosisHomocysteine and Atherosclerosis
Homocysteine and AtherosclerosisAde Wijaya
 
Introduction to leukemia
Introduction to leukemia Introduction to leukemia
Introduction to leukemia ebtihal babekir
 
2 atherosclerosis pathology
2 atherosclerosis pathology2 atherosclerosis pathology
2 atherosclerosis pathologyPNK SINGH
 
Atherosclerosis
AtherosclerosisAtherosclerosis
AtherosclerosisEneutron
 
Atherosclerosis-All about Atherosclerosis,intoduction, causes, pathophysiolog...
Atherosclerosis-All about Atherosclerosis,intoduction, causes, pathophysiolog...Atherosclerosis-All about Atherosclerosis,intoduction, causes, pathophysiolog...
Atherosclerosis-All about Atherosclerosis,intoduction, causes, pathophysiolog...Archana Mandava
 
SLE by DRMAGDI SASI 2016
SLE by DRMAGDI SASI 2016SLE by DRMAGDI SASI 2016
SLE by DRMAGDI SASI 2016cardilogy
 
Prevalence of hypochromic microcytic anemia in the Hematology-oncology depart...
Prevalence of hypochromic microcytic anemia in the Hematology-oncology depart...Prevalence of hypochromic microcytic anemia in the Hematology-oncology depart...
Prevalence of hypochromic microcytic anemia in the Hematology-oncology depart...Premier Publishers
 

What's hot (20)

Cvs as-csbrp
Cvs as-csbrpCvs as-csbrp
Cvs as-csbrp
 
Atherosclerosis and myocardial infarction
Atherosclerosis and myocardial infarctionAtherosclerosis and myocardial infarction
Atherosclerosis and myocardial infarction
 
atherosclerosis
atherosclerosisatherosclerosis
atherosclerosis
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Coronary atherosclerosis (6)
Coronary atherosclerosis (6)Coronary atherosclerosis (6)
Coronary atherosclerosis (6)
 
Leukemia --acute myeloid leukemia --- magdi sasi
Leukemia  --acute myeloid leukemia --- magdi sasiLeukemia  --acute myeloid leukemia --- magdi sasi
Leukemia --acute myeloid leukemia --- magdi sasi
 
atherosclerosis
atherosclerosisatherosclerosis
atherosclerosis
 
Homocysteine and Atherosclerosis
Homocysteine and AtherosclerosisHomocysteine and Atherosclerosis
Homocysteine and Atherosclerosis
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Introduction to leukemia
Introduction to leukemia Introduction to leukemia
Introduction to leukemia
 
2 atherosclerosis pathology
2 atherosclerosis pathology2 atherosclerosis pathology
2 atherosclerosis pathology
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
Atherosclerosis-All about Atherosclerosis,intoduction, causes, pathophysiolog...
Atherosclerosis-All about Atherosclerosis,intoduction, causes, pathophysiolog...Atherosclerosis-All about Atherosclerosis,intoduction, causes, pathophysiolog...
Atherosclerosis-All about Atherosclerosis,intoduction, causes, pathophysiolog...
 
Austin Leukemia
Austin LeukemiaAustin Leukemia
Austin Leukemia
 
LEUKEMIA
LEUKEMIALEUKEMIA
LEUKEMIA
 
Leukemia
LeukemiaLeukemia
Leukemia
 
SLE by DRMAGDI SASI 2016
SLE by DRMAGDI SASI 2016SLE by DRMAGDI SASI 2016
SLE by DRMAGDI SASI 2016
 
Prevalence of hypochromic microcytic anemia in the Hematology-oncology depart...
Prevalence of hypochromic microcytic anemia in the Hematology-oncology depart...Prevalence of hypochromic microcytic anemia in the Hematology-oncology depart...
Prevalence of hypochromic microcytic anemia in the Hematology-oncology depart...
 
Atherosclerosis
AtherosclerosisAtherosclerosis
Atherosclerosis
 
4 causes of leukemia
4 causes of leukemia 4 causes of leukemia
4 causes of leukemia
 

Similar to Caso clinico dra carmen

259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factorSHAPE Society
 
Beyond Framingham
Beyond FraminghamBeyond Framingham
Beyond Framinghamhospital
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002SHAPE Society
 
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Cleveland HeartLab, Inc.
 
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...asclepiuspdfs
 
Lipoprotein associated phospholipase a2
Lipoprotein associated phospholipase a2Lipoprotein associated phospholipase a2
Lipoprotein associated phospholipase a2Saroj Kundan
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calciumSHAPE Society
 
10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-xAndi Wahyudi
 
Presentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. BotsPresentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. BotsCVON
 
Serum uric acid as a marker of left ventricular failure in acute myocardial i...
Serum uric acid as a marker of left ventricular failure in acute myocardial i...Serum uric acid as a marker of left ventricular failure in acute myocardial i...
Serum uric acid as a marker of left ventricular failure in acute myocardial i...iosrjce
 

Similar to Caso clinico dra carmen (20)

259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
Esv2n47
Esv2n47Esv2n47
Esv2n47
 
259 crp as a risk factor
259 crp as a risk factor259 crp as a risk factor
259 crp as a risk factor
 
Beyond Framingham
Beyond FraminghamBeyond Framingham
Beyond Framingham
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002
 
234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002234 aha 2002 guideline, 1997 or 2002
234 aha 2002 guideline, 1997 or 2002
 
Esv2n29
Esv2n29Esv2n29
Esv2n29
 
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...Marc Penn,  MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
Marc Penn, MD, PhD, FACC - Trials and Tribulations of Assessing CVD Risk in ...
 
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
Diagnosis of Early Risks, Management of Risks, and Reduction of Vascular Dise...
 
Lipoprotein associated phospholipase a2
Lipoprotein associated phospholipase a2Lipoprotein associated phospholipase a2
Lipoprotein associated phospholipase a2
 
Herrick et al _JCDR 2014
Herrick et al _JCDR 2014Herrick et al _JCDR 2014
Herrick et al _JCDR 2014
 
Fuster aha-2005-dallas-biomarkers,
Fuster  aha-2005-dallas-biomarkers,Fuster  aha-2005-dallas-biomarkers,
Fuster aha-2005-dallas-biomarkers,
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium251 computed tomographic coronary artery calcium
251 computed tomographic coronary artery calcium
 
Es v2n43
Es v2n43Es v2n43
Es v2n43
 
10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x10.1007@s10067 018-04416-x
10.1007@s10067 018-04416-x
 
BIOMARKERS IN HF.pptx
BIOMARKERS IN HF.pptxBIOMARKERS IN HF.pptx
BIOMARKERS IN HF.pptx
 
CVD-Report-V1.pdf
CVD-Report-V1.pdfCVD-Report-V1.pdf
CVD-Report-V1.pdf
 
Presentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. BotsPresentatie Prof. dr. Deckers en Prof. dr. Bots
Presentatie Prof. dr. Deckers en Prof. dr. Bots
 
Serum uric acid as a marker of left ventricular failure in acute myocardial i...
Serum uric acid as a marker of left ventricular failure in acute myocardial i...Serum uric acid as a marker of left ventricular failure in acute myocardial i...
Serum uric acid as a marker of left ventricular failure in acute myocardial i...
 

More from YOJANNA PERDOMO DOMINGUEZ

Factores independientes de riesgo cardiovascular bases bioqu
Factores independientes de riesgo cardiovascular bases bioquFactores independientes de riesgo cardiovascular bases bioqu
Factores independientes de riesgo cardiovascular bases bioquYOJANNA PERDOMO DOMINGUEZ
 
Caso clinico correlacion 2015 aparasitologia
Caso clinico correlacion 2015 aparasitologiaCaso clinico correlacion 2015 aparasitologia
Caso clinico correlacion 2015 aparasitologiaYOJANNA PERDOMO DOMINGUEZ
 

More from YOJANNA PERDOMO DOMINGUEZ (20)

Articulo clase mayo 2016
Articulo clase mayo 2016Articulo clase mayo 2016
Articulo clase mayo 2016
 
Manejo de pacientes con sospecha iam
Manejo de pacientes con sospecha iamManejo de pacientes con sospecha iam
Manejo de pacientes con sospecha iam
 
Ateriosclerosis e infarto tisular
Ateriosclerosis e infarto tisularAteriosclerosis e infarto tisular
Ateriosclerosis e infarto tisular
 
Factores independientes de riesgo cardiovascular bases bioqu
Factores independientes de riesgo cardiovascular bases bioquFactores independientes de riesgo cardiovascular bases bioqu
Factores independientes de riesgo cardiovascular bases bioqu
 
Notas de participacion bioquimica
Notas de participacion bioquimicaNotas de participacion bioquimica
Notas de participacion bioquimica
 
Casos clinicos de baar
Casos clinicos de baarCasos clinicos de baar
Casos clinicos de baar
 
Case clinical cardiaca
Case clinical cardiacaCase clinical cardiaca
Case clinical cardiaca
 
Caso clinico uroanalisis
Caso clinico uroanalisisCaso clinico uroanalisis
Caso clinico uroanalisis
 
Caso clinico blog
Caso clinico blogCaso clinico blog
Caso clinico blog
 
Caso clinico funcion hepatica v2
Caso clinico funcion hepatica v2Caso clinico funcion hepatica v2
Caso clinico funcion hepatica v2
 
Caso clínico blog anemias 2015 b
Caso clínico blog anemias 2015 bCaso clínico blog anemias 2015 b
Caso clínico blog anemias 2015 b
 
NOTAS PARTICIPATIVAS 10%
NOTAS PARTICIPATIVAS 10%NOTAS PARTICIPATIVAS 10%
NOTAS PARTICIPATIVAS 10%
 
Lepra del ins
Lepra del insLepra del ins
Lepra del ins
 
Coagulacion en cirrosis
Coagulacion en cirrosisCoagulacion en cirrosis
Coagulacion en cirrosis
 
Fisiopatología de la diarrea aguda
Fisiopatología de la diarrea agudaFisiopatología de la diarrea aguda
Fisiopatología de la diarrea aguda
 
Caso clinico bioquimica
Caso clinico bioquimicaCaso clinico bioquimica
Caso clinico bioquimica
 
Caso clinico del blog preguntas ingles
Caso clinico del blog preguntas inglesCaso clinico del blog preguntas ingles
Caso clinico del blog preguntas ingles
 
Articulo resistencia microbina ingles
Articulo resistencia microbina inglesArticulo resistencia microbina ingles
Articulo resistencia microbina ingles
 
Caso clinico correlacion 2015 aparasitologia
Caso clinico correlacion 2015 aparasitologiaCaso clinico correlacion 2015 aparasitologia
Caso clinico correlacion 2015 aparasitologia
 
Caso clinico funcion hepatica v2
Caso clinico funcion hepatica v2Caso clinico funcion hepatica v2
Caso clinico funcion hepatica v2
 

Caso clinico dra carmen

  • 1. Interprete el siguiente documento y establezca la importancia de cada una de las pruebas que allí se anuncian, elabore un ensayo (una hoja) y preparese para foro de discusión a desarrollar en la clase de correlación clínica se recomienda para ello llevar información. The Global Epidemic of Cardiovascular Disease – Diagnostic Standards and the Role of the Clinical Laboratory in Primary and Secondary Prevention and Risk Stratification Professor M. J. McQueen There is a global epidemic of atherosclerosis and the future disease burden is probably underestimated because projections do not account for potential increases in risk factors such as obesity, diabetes, dyslipidemia, hypertension, smoking, and urbanization. Population based studies now suggest that 80% to 90% of CVD susceptibility can be explained by a relatively small number of “classical” risk factors. However, myocardial infarction occurs in up to 50% of people without significant lipid abnormalities and this has led to the investigation of novel risk factors such as lipoprotein(a), ApoA1, ApoB, homocysteine, inflammatory markers, infectious markers, and oxidative stress factors. The clinical laboratory has a significant role in diagnosis, risk stratification, management and prognosis in acute coronary syndromes, as well as the primary and secondary prevention of cardiovascular disease. Myocardial infarction has been re-defined, giving primacy to the rise and fall of biochemical markers of myocardial necrosis (troponin/CK-MB) accompanied by at least one of several symptoms and signs. This has created analytical issues for the clinical laboratory. The biochemical markers may be cardio-specific but there is still not one which is ischemic heart disease specific, so various markers for myocardial ischemia have been investigated. Inflammatory markers have been shown to have prognostic value in identifying those patients with acute coronary syndrome who are at greater risk of death or myocardial infarction. For primary and secondary prevention of cardiovascular disease, lipids and lipoproteins, LP(a), homocysteine, and many inflammatory markers such as oxidized LDL, IL1, TNF-α, ICAM, VCAM, selectins, IL6, SAA, and CRP have all been investigated. The evidence for hsCRP as a risk marker for subsequent cardiovascular events is more clearly demonstrated in primary prevention than secondary prevention cohorts. Data will be presented from our Heart Outcomes Prevention Evaluation (HOPE) study relating to inflammatory markers, multiple infection, heat shock proteins and their relative risk for subsequent cardiovascular events. There is a need for more research to further define the approach to therapeutic decision making, using markers of inflammation, infection, and ventricular dysfunction (eg, natriuretic peptides). File:shd.CV abstract